Ezzeldin M Ibrahim

Summary

Publications

  1. ncbi request reprint Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies
    Ezzeldin M Ibrahim
    Oncology Center, International Medical Center, PO Box 2172, Jeddah, 21451, Kingdom of Saudi Arabia
    Med Oncol 28:753-65. 2011
  2. pmc Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, Jeddah, Saudi Arabia
    Ann Thorac Med 5:153-60. 2010
  3. doi request reprint Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah, 21451, Kingdom of Saudi Arabia
    Int J Clin Oncol 18:1060-9. 2013
  4. doi request reprint Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, P O Box 2172, Jeddah, 21451, Kingdom of Saudi Arabia
    Lung 191:117-34. 2013
  5. pmc Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Saudi Arabia
    BMC Cancer 12:197. 2012
  6. doi request reprint Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Kingdom of Saudi Arabia
    Med Oncol 28:S310-7. 2011
  7. doi request reprint Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, Kingdom of Saudi Arabia
    Lung 189:193-8. 2011
  8. ncbi request reprint Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer
    Ezzeldin M Ibrahim
    Department of Oncology and Hematology, Sections of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
    Indian J Cancer 44:56-61. 2007
  9. doi request reprint Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia
    Ezzeldin M Ibrahim
    Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia
    Asia Pac J Clin Oncol 6:130-7. 2010
  10. doi request reprint The present and the future of breast cancer burden in the Kingdom of Saudi Arabia
    Ezzeldin M Ibrahim
    King Faisal Hospital and Research Center, Jeddah, Saudi Arabia
    Med Oncol 25:387-93. 2008

Collaborators

  • Meteb Al-Foheidi
  • Mubarak M Al-Mansour

Detail Information

Publications14

  1. ncbi request reprint Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies
    Ezzeldin M Ibrahim
    Oncology Center, International Medical Center, PO Box 2172, Jeddah, 21451, Kingdom of Saudi Arabia
    Med Oncol 28:753-65. 2011
    ..The current meta-analysis provides evidence for an inverse relationship between PA and mortality in patients with breast cancer and supports the notion that appropriate PA should be embraced by breast cancer survivors...
  2. pmc Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, Jeddah, Saudi Arabia
    Ann Thorac Med 5:153-60. 2010
    ..RATIONAL: The inconsistent results and the lack published meta-analysis that systematically examined the overall efficacy of gefitinib in the frontline setting in such patients, have prompted the current meta-analysis...
  3. doi request reprint Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah, 21451, Kingdom of Saudi Arabia
    Int J Clin Oncol 18:1060-9. 2013
    ..The significant variation in the reported incidences of AEs has prompted this meta-analysis to quantify the risk and explore associated predictors...
  4. doi request reprint Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, P O Box 2172, Jeddah, 21451, Kingdom of Saudi Arabia
    Lung 191:117-34. 2013
    ..The aim of this meta-analysis was to quantify such risk and to analyze contributing risk factors in HL survivors...
  5. pmc Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Saudi Arabia
    BMC Cancer 12:197. 2012
    ..We planned this meta-analysis to quantify the long-term risk of SBC and analyze the contributing risk factors among HL survivors...
  6. doi request reprint Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Kingdom of Saudi Arabia
    Med Oncol 28:S310-7. 2011
    ..The benefit was demonstrated in most subgroup analyses. Further research to better define potential responders is needed...
  7. doi request reprint Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials
    Ezzeldin M Ibrahim
    Oncology Center of Excellence, International Medical Center, Kingdom of Saudi Arabia
    Lung 189:193-8. 2011
    ..CBT produced significant clinical benefit with acceptable toxicity as a first-line strategy in patients with advanced/metastatic NSCLC. Further research is needed to identify markers predictive of cetuximab benefit in that disease...
  8. ncbi request reprint Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer
    Ezzeldin M Ibrahim
    Department of Oncology and Hematology, Sections of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
    Indian J Cancer 44:56-61. 2007
    ..This prospective phase-II study was designed to assess the efficacy and safety of CBCC as first-, second- or third-line among Saudi patients with mCRC...
  9. doi request reprint Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia
    Ezzeldin M Ibrahim
    Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia
    Asia Pac J Clin Oncol 6:130-7. 2010
    ..Because of such features, it is necessary to examine prognostic factors in this population. One such factor is the prognostic role of lymph node ratio (LNR)...
  10. doi request reprint The present and the future of breast cancer burden in the Kingdom of Saudi Arabia
    Ezzeldin M Ibrahim
    King Faisal Hospital and Research Center, Jeddah, Saudi Arabia
    Med Oncol 25:387-93. 2008
    ..This work was designed to study female breast cancer as a model to assess future cancer burden and the impact on healthcare resources...
  11. ncbi request reprint Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries
    Meteb Al-Foheidi
    Princess Noorah Oncology Center, King Abdulaziz Medical City, PO Box 9515, Jeddah 21423, Kingdom of Saudi Arabia
    Med Oncol 30:471. 2013
    ..We also provide recommendations concerning rational preventive strategies for breast cancer control for women in DLICs...
  12. doi request reprint Folic acid supplementation for the prevention of recurrence of colorectal adenomas: metaanalysis of interventional trials
    Ezzeldin M Ibrahim
    Department of Medicine and Oncology, King Faisal Specialist Hospital and Research Center, PO Box 40047, Jeddah, 21499, Kingdom of Saudi Arabia
    Med Oncol 27:915-8. 2010
    ..Future trials should examine the effect of different dosage and duration. Moreover, the confounding effect of dietary and life style habits should be carefully controlled...
  13. pmc Past, present and future of colorectal cancer in the kingdom of saudi arabia
    Ezzeldin M Ibrahim
    Department of Oncology and Hematology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia
    Saudi J Gastroenterol 14:178-82. 2008
    ..Pragmatic recommendations to face that challenge are discussed. The present work could serve as a model to study other prevalent types of cancer, particularly in developing countries...
  14. ncbi request reprint Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia
    Ezzeldin M Ibrahim
    Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia
    Med Oncol 22:343-52. 2005
    ....